In Alzheimer's disease, amyloid plaques form in the brain, followed by threadlike structures made of the protein tau. Both changes have toxic effects on the brain's nerve cells years before dementia symptoms appear. Historically, diagnosis has primarily relied on cognitive changes, which manifest at a later stage of the disease. Biomarker-based diagnostics were initially limited to specialized clinics capable of performing cerebrospinal fluid sampling or PET scans.